Magnesium Carbonate
drugOn this page
Also known as AndrewsAnhydrous magnesium carbonateC.I. 77713E-504(i)E504Ins no.504(i)Ins-504(i)Light magnesium carbonateMag carbMag carb aromMag carb coMagnesia carbonicaMagnesiteMagnesite (mg(co3))Magnesium (as carbonate)Magnesium carbonate (1:1) hydrateMagnesium carbonate anhydrousMagnesium carbonate gold starMagnesium carbonate light
Summary
Magnesium Carbonate (CHEMBL1200736) is an approved small-molecule antacid (ATC A06AD01); indicated across 1 condition including constipation disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A06AD01 (+1 more)
- Indications: 1 condition
- Clinical trials: 3
- Chemistry: 84.31 Da · CMgO3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200736 |
| Name | Magnesium Carbonate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 11029 |
| ChEBI | CHEBI:31793 |
| ATC | A06AD01, A02AA01 |
| Molecular formula | CMgO3 |
| Molecular weight | 84.31 |
| InChIKey | ZLNQQNXFFQJAID-UHFFFAOYSA-L |
SMILES: C(=O)([O-])[O-].[Mg+2]
IUPAC name: magnesium carbonate
ChEBI definition: A magnesium salt with formula CMgO3. Its hydrated forms, particularly the di-, tri-, and tetrahydrates occur as minerals.
Pharmacological roles (ChEBI): antacid.
Other ChEBI roles (chemical / environmental): fertilizer.
Also known as: Andrews, Anhydrous magnesium carbonate, C.I. 77713, E-504(i), E504, Ins no.504(i), Ins-504(i), Light magnesium carbonate, Mag carb, Mag carb arom, Mag carb co, Magnesia carbonica
Patent coverage: 112,795 distinct patent families (329,789 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| constipation disorder | 4 | MONDO:0002203 | HP:0002019 |
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00212745 | PHASE1/PHASE2 | COMPLETED | Pilot Trial of a Behavioral Treatment for Epilepsy |
| NCT01935570 | PHASE1 | COMPLETED | Comparative Study of the Bioavailability of Magnesium Administrated by Two ChronoMag Smart Tablet® 50 mg Versus Three Mag2® Tablets 100mg. |
| NCT01533649 | Not specified | UNKNOWN | Personalizing Health Outcome in Epilepsy Now - An Introduction to Clinical Services |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: constipation disorder